Frazier Life Sciences Acquisition Corp. II filed an audited balance sheet as of October 15, 2026, reflecting the consummation of its initial public offering (IPO) and a concurrent private placement. The blank check company raised gross proceeds of $75,000,000 through the sale of 7,500,000 Class A ordinary shares at $10.00 per share. Simultaneously, the Company completed a private placement of 300,000 Class A ordinary shares at the same price, generating an additional $3,000,000 in gross proceeds.
According to the filing, a total of $75,000,000 from the IPO proceeds was deposited into a U.S.-based trust account managed by Continental Stock Transfer & Trust Company. The Company reported total assets of $76,837,481 as of October 15, 2026, consisting of $75,000,000 in cash held in the trust account and $1,837,481 in current assets. The Company reported total liabilities of $3,063,953, primarily consisting of a $3,000,000 deferred underwriting fee payable and $63,953 in current liabilities.
The audited financial statements indicate that the Company has not commenced any operations and generated no operating revenues. The Company’s sponsor, Frazier Life Sciences Holdings II, LLC, purchased the private placement shares. The filing notes that the Company must complete a business combination with an aggregate fair market value of at least 80% of the net assets held in the trust account to proceed.
